Actively warming patients to achieve normal body temperature in the perioperative period is the standard of care, largely endorsed by: CMS, AHA, CDC, IHI, TJC, Surgical Infection Prevention Project (SIPP) and most recently the Surgical Care Improvement Project (SCIP).
Current technologies to maintain normal body temperature don’t take into account the body’s complex, natural thermoregulatory system, interfere with the surgeon workspace, are sometimes inefficient, and have led to patient infections, injuries and fatalities.
Mercury recognizes that there is a tremendous market opportunity to provide better temperature management solutions that reduce the likelihood of harm to patients and improve the standard of care. Thanks to its diverse team, patented technology, and clinical support, Mercury is primed to seize that opportunity. Mercury intends to do this by creating a system that provides a harmonious interaction in the OR and with the patient.
The U.S. market for temperature management solutions is large, with the current market for surgical warming devices at $1.6 billion with a CAGR of 7.76%, and $665 million for cooling devices, with a CAGR of 6.54%. The total global market for therapeutic temperature management devices exceeds $2.2 billion.
Private Payer and Medicare reimbursement for maintenance of core body temperature and induction of mild therapeutic hypothermia is already well established both in the U.S. and Europe.